Abstract YO26
Case summary
As the survival of patients with brain metastases is being prolonged, due to improved systemic therapy, opportunities to use immune checkpoint inhibitor (ICI)s after SRT (stereotactic radiotherapy) or IMRT (Intensity Modulated Radiation Therapy) in patient with brain metastases are increasing. Radiation necrosis is known as a late toxicity of SRT and IMRT. However, few studies have examined the association between ICIs and radiation necrosis. Here we report two cases in which radiation necrosis was exacerbated after ICIs.
Case1: A 30-year-old female diagnosed with nasopharyngeal carcinoma who had direct invasion to the skull base and metastases to the vertebrae. After the concurrent chemoradiation, she had a locoregional recurrence. MRI showed the ring-enhancing lesion around the IMRT-pretreated site of the right temporal lobe, which was considered to be radiation necrosis. One week after the initiation of nivolumab, the patient developed disorientation and a headache. Brain CT showed the exacerbation of radiation necrosis. Corticosteroid administration improved the symptoms. Nivolumab was not reinitiated.
Case2: A 60-year-old male diagnosed with non-small cell lung cancer with brain metastases. He underwent IMRT for the right temporal lobe after undergoing bilateral craniotomy for multiple brain metastases. Because the paralysis progressed, he was performed resection of the brain enhancing lesion. The histopathological examination of the resected brain lesion revealed the presence of diffuse necrosis and gliosis with absence of viable tumor, which was compatible with radiation necrosis. One week after the initiation of atezolizumab, the patient developed hemiparesis. Brain CT showed the exacerbation of radiation necrosis. The patient then started treatment with corticosteroid, and hemiparesis was partly improved. The administration of atezolizumab was discontinued.
Conclusion: We experienced two cases of exacerbation of radiation necrosis following the initiation of the ICIs. Further investigation for the safety of using ICIs in patients with radiation necrosis is warranted.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract